Rokote Laboratories signs an agreement with 3PBIOVIAN for GMP manufacturing of adenovirus vector-based COVID-19 vaccine August 29, 2024 Read more >
Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN, a leading pan-European biologics CDMO February 1, 2024 Read more >
3P Biopharmaceuticals: building a legacy of innovation and excellence in biotechnology December 20, 2023 Read more >
3P Biopharmaceuticals and the University of Navarra bring the Neanderthal world and biomedicine to the public in a successful event. October 19, 2023 Read more >
3P Biopharmecuiticals celebrates cerebral palsy day in collaboration with ASPACE October 6, 2023 Read more >
3P Biopharmaceuticals continues its successful collaboration with Toleranzia AB to fight Myasthenia Gravis. September 19, 2023 Read more >
3P Biopharmaceuticals continues its collaboration with U.S. biotech Zhittya for the treatment of Parkinson’s disease. May 2, 2023 Read more >
The Regional Minister for Economic and Business Development Mikel Irujo meets with the management of 3P Biopharmaceuticals and its majority shareholder Keensight Capital. March 23, 2023 Read more >
3P Biopharmaceuticals is moving forward with its expansion plan and the adaptation of its facilities. March 9, 2023 Read more >
3P Biopharmaceuticals increases its microbial production capacity with the installation of a 500 L fermenter. March 1, 2023 Read more >
3P Biopharmaceuticals brings together leading international experts in biomedicine to celebrate its 15th anniversary. December 1, 2022 Read more >
BrainEver and 3P Biopharmaceuticals collaborate on development of recombinant human homeoprotein Engrailed-1 November 15, 2022 Read more >
3P Biopharmaceuticals among the 100 best companies to work for in Spain September 27, 2022 Read more >
3P Biopharmaceuticals celebrates its 15th anniversary with Juan Carlos Unzué. July 29, 2022 Read more >